HRP20200592T1 - Nova anti-il 13 antitijela i njihove uporabe - Google Patents
Nova anti-il 13 antitijela i njihove uporabe Download PDFInfo
- Publication number
- HRP20200592T1 HRP20200592T1 HRP20200592TT HRP20200592T HRP20200592T1 HR P20200592 T1 HRP20200592 T1 HR P20200592T1 HR P20200592T T HRP20200592T T HR P20200592TT HR P20200592 T HRP20200592 T HR P20200592T HR P20200592 T1 HRP20200592 T1 HR P20200592T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- antibody
- human
- preparation according
- pharmaceutical preparation
- Prior art date
Links
- 102000003816 Interleukin-13 Human genes 0.000 claims abstract 14
- 108090000176 Interleukin-13 Proteins 0.000 claims abstract 14
- 208000006673 asthma Diseases 0.000 claims abstract 6
- 101100286681 Homo sapiens IL13 gene Proteins 0.000 claims abstract 5
- 208000010668 atopic eczema Diseases 0.000 claims abstract 5
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims abstract 3
- 201000010105 allergic rhinitis Diseases 0.000 claims abstract 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims abstract 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims abstract 2
- 201000004624 Dermatitis Diseases 0.000 claims abstract 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract 2
- 208000004262 Food Hypersensitivity Diseases 0.000 claims abstract 2
- 101100286685 Mus musculus Il13 gene Proteins 0.000 claims abstract 2
- 208000001132 Osteoporosis Diseases 0.000 claims abstract 2
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims abstract 2
- 206010039710 Scleroderma Diseases 0.000 claims abstract 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims abstract 2
- 208000024780 Urticaria Diseases 0.000 claims abstract 2
- 206010046851 Uveitis Diseases 0.000 claims abstract 2
- 201000009961 allergic asthma Diseases 0.000 claims abstract 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims abstract 2
- 208000024998 atopic conjunctivitis Diseases 0.000 claims abstract 2
- 230000000694 effects Effects 0.000 claims abstract 2
- 235000020932 food allergy Nutrition 0.000 claims abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 206010012434 Dermatitis allergic Diseases 0.000 claims 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- 101100227726 Arabidopsis thaliana FRL3 gene Proteins 0.000 claims 1
- 101100120609 Caenorhabditis elegans frh-1 gene Proteins 0.000 claims 1
- 101150023991 FMNL1 gene Proteins 0.000 claims 1
- 101150005226 FRL1 gene Proteins 0.000 claims 1
- 101150065691 FRL2 gene Proteins 0.000 claims 1
- 206010016946 Food allergy Diseases 0.000 claims 1
- 102100028930 Formin-like protein 1 Human genes 0.000 claims 1
- 102100032789 Formin-like protein 3 Human genes 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000036783 anaphylactic response Effects 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 101150029401 fmnl3 gene Proteins 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 201000010659 intrinsic asthma Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Claims (12)
1. Farmaceutski pripravak koji sadrži antagonističko anti-ljudsko IL13 antitijelo ili njegov fragment vezan za antigen koji se specifično veže na ljudski IL13 i fiziološki prihvatljiv nosač, naznačen time što navedeno anti-ljudsko IL13 antitijelo sadrži varijabilnu regiju teškog lanca koja sadrži regije koje određuju komplementarnost CDRH1, CDRH2 i CDRH3 koje imaju aminokiselinske sekvence od SEQ ID NO: 117, SEQ ID NO: 123, i SEQ ID NO: 135, odnosno, i varijabilnu regiju lakog lanca koja sadrži regije koje određuju komplementarnost CDRL1, CDRL2 i CDRL3 koji imaju aminokiselinske sekvence od SEQ ID NO: 99, SEQ ID NO: 104, i SEQ ID NO: 115, odnosno, i pri čemu je navedeno anti-ljudsko IL13 antitijelo ili njegov funkcionalni fragment formulirano da se daje intravenski, intraperitonealno, intramuskularno, subkutano ili oralno.
2. Farmaceutski pripravak prema zahtjevu 1, naznačen time što je navedeno anti-ljudsko IL13 antitijelo humanizirano antitijelo.
3. Farmaceutski pripravak prema zahtjevu 1 ili 2, naznačen time što navedeno anti-ljudsko IL13 antitijelo sadrži varijabilnu regiju teškog lanca koja sadrži aminokiselinsku sekvencu formule: FRH1-CDRH1-FRH2-CDRH2-FRH3-CDRH3-FRH4, pri čemu se FRH1 sastoji od SEQ ID NO: 65; CDRHl se sastoji od SEQ ID NO: 117; FRH2 se sastoji od SEQ ID NO: 68; CDRH2 se sastoji od SEQ ID NO: 123; FRH3 se sastoji od SEQ ID NO: 80; CDRH3 se sastoji od SEQ ID NO: 135; i FRH4 se sastoji od SEQ ID NO: 92 i varijabilne regije lakog lanca koja sadrži aminokiselinsku sekvencu formule: FRL1-CDRL1-FRL2-CDRL2-FRL3-CDRL3-FRL4, pri čemu se FRL1 sastoji od SEQ ID NO: 21; CDRL1 sastoji se od SEQ ID NO: 99; FRL2 se sastoji od SEQ ID NO: 29; CDRL2 se sastoji od SEQ ID NO: 104; FRL3 se sastoji od SEQ ID NO: 31; CDRL3 se sastoji od SEQ ID NO: 115; i FRL4 se sastoji od SEQ ID NO: 58.
4. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 3, naznačen time što navedeno anti-ljudsko IL13 antitijelo sadrži varijabilnu regiju lakog lanca koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 142 i varijabilnu regiju teškog lanca koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 143.
5. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 4, naznačen time što se navedeno anti-ljudsko IL13 antitijelo ili njegov fragment vezan za antigen veže specifično i s visokim afinitetom na glikoziliranu i ne-glikoziliranu ljudsku IL13, ne veže mišju IL13 i neutralizira ljudsku IL13 aktivnost pri približnom molarnom omjeru 1: 2 (MAb: IL13).
6. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 5, naznačen time što se navedeno anti-ljudsko IL13 antitijelo ili njegov fragment vezan za antigen veže na isti epitop kao i antitijelo proizvedeno hibridomom 228B/C-1 (PTA-5657).
7. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 6, naznačen time što je navedeno antitijelo IL13 antitijelo monoklonsko antitijelo.
8. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 7, naznačen time što je navedeno anti-IL13 antitijelo monovalentno antitijelo, multispecifično antitijelo, antitijelo s jednim lancem, Fab fragment ili F (ab') fragment.
9. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 8, naznačen time što je navedeno anti-ljudsko-IL13 antitijelo multispecifično antitijelo koje je bispecifično antitijelo.
10. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 9, za uporabu u prevenciji bronhijalne astme, alergijskog rinitisa, alergijskog dermatitisa ili anafilaksije.
11. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 9, za uporabu u liječenju bronhijalne astme, alergijske astme, nealergijske astme, alergijskog rinitisa, atopijskog dermatitisa, alergijskog dermatitisa, alergijskog konjuktivitisa, ekcema, urtikarije, alergije na hranu, kronične opstruktivne plućne bolesti, ulceroznog kolitisa, RSV infekcije, uveitisa, skleroderma ili osteoporoze.
12. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 9, za uporabu u liječenju idiopatske plućne fibroze ili upalne i fibrotičke bolesti pluća.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53213003P | 2003-12-23 | 2003-12-23 | |
EP14164624.0A EP2805728B1 (en) | 2003-12-23 | 2004-12-23 | Novel anti-IL 13 antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20200592T1 true HRP20200592T1 (hr) | 2020-08-07 |
Family
ID=34738751
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20231569TT HRP20231569T1 (hr) | 2003-12-23 | 2004-12-23 | Nova protutijela protiv il 13 i njihova upotreba |
HRP20120376TT HRP20120376T1 (hr) | 2003-12-23 | 2012-05-03 | Nova protutijela protiv il-13 i njihove upotrebe |
HRP20200592TT HRP20200592T1 (hr) | 2003-12-23 | 2020-04-14 | Nova anti-il 13 antitijela i njihove uporabe |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20231569TT HRP20231569T1 (hr) | 2003-12-23 | 2004-12-23 | Nova protutijela protiv il 13 i njihova upotreba |
HRP20120376TT HRP20120376T1 (hr) | 2003-12-23 | 2012-05-03 | Nova protutijela protiv il-13 i njihove upotrebe |
Country Status (24)
Country | Link |
---|---|
US (10) | US8067199B2 (hr) |
EP (6) | EP2351584A1 (hr) |
JP (5) | JP4943161B2 (hr) |
KR (5) | KR20120020203A (hr) |
CN (4) | CN102993302B (hr) |
AT (1) | ATE552850T1 (hr) |
AU (1) | AU2004308494B2 (hr) |
CA (2) | CA2551110C (hr) |
CY (2) | CY1113009T1 (hr) |
DK (4) | DK3718564T3 (hr) |
ES (4) | ES2533084T3 (hr) |
FI (1) | FI3718564T3 (hr) |
HK (3) | HK1108007A1 (hr) |
HR (3) | HRP20231569T1 (hr) |
HU (1) | HUE049161T2 (hr) |
IL (2) | IL176042A (hr) |
LT (2) | LT2805728T (hr) |
MX (1) | MX361174B (hr) |
PL (4) | PL2805728T3 (hr) |
PT (3) | PT3718564T (hr) |
RU (3) | RU2487887C2 (hr) |
SG (4) | SG151296A1 (hr) |
SI (4) | SI1711528T1 (hr) |
WO (2) | WO2005062972A2 (hr) |
Families Citing this family (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7883704B2 (en) * | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
GB0407315D0 (en) | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
JP4943161B2 (ja) | 2003-12-23 | 2012-05-30 | ジェネンテック, インコーポレイテッド | 新規抗il13モノクローナル抗体での癌の処置 |
EP1713441A2 (en) * | 2004-02-12 | 2006-10-25 | Nektar Therapeutics | Interleukin-13 antagonist powders, spray-dried particles, and methods |
EP2168986A3 (en) | 2004-02-19 | 2010-07-28 | Genentech, Inc. | CDR-repaired antibodies |
AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
US20090098142A1 (en) * | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
WO2006055638A2 (en) * | 2004-11-17 | 2006-05-26 | Abgenix, Inc. | Fully human monoclonal antibodies to il-13 |
KR101363777B1 (ko) * | 2005-09-30 | 2014-02-14 | 메디뮨 리미티드 | 인터루킨―13 항체 조성물 |
US20070202106A1 (en) * | 2005-10-06 | 2007-08-30 | Baylor Research Institute | Compositions and methods for the treatment of cancer |
CA2658833A1 (en) * | 2005-10-06 | 2007-04-19 | Baylor Research Institute | Compositions and methods for the treatment of cancer |
EP2532679B1 (en) | 2005-10-21 | 2017-04-12 | Novartis AG | Human antibodies against il13 and therapeutic uses |
KR101439828B1 (ko) | 2005-11-30 | 2014-09-17 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
GB0600488D0 (en) * | 2006-01-11 | 2006-02-22 | Glaxo Group Ltd | Immunoglobulins |
CN101578298A (zh) * | 2006-01-24 | 2009-11-11 | 杜门蒂斯有限公司 | 结合il-4和/或il-13的配体 |
EP2471816A1 (en) | 2006-08-30 | 2012-07-04 | Genentech, Inc. | Multispecific antibodies |
ES2902063T3 (es) * | 2006-09-08 | 2022-03-24 | Abbvie Bahamas Ltd | Proteínas de unión a interleucina-13 |
NZ578065A (en) | 2007-01-16 | 2012-09-28 | Abbott Lab | Methods for treating psoriasis with an antibody which binds to an epitope |
MX2009011366A (es) * | 2007-04-23 | 2009-11-05 | Wyeth Corp | Metodos y composiciones para tratar y monitorear el tratamiento de trastornos asociados con il-13. |
WO2008140455A1 (en) * | 2007-05-15 | 2008-11-20 | Tanox, Inc. | Treatment of radiation and chemo-therapy induced fibrosis using novel anti-il 13 monoclonal antibodies |
US8183982B2 (en) | 2007-08-14 | 2012-05-22 | Infineon Technologies Ag | System including reply signal that at least partially overlaps request |
CN103223165B (zh) | 2007-08-24 | 2015-02-11 | 学校法人庆应义塾 | 肿瘤细胞所导致的免疫抑制的解除剂及使用该解除剂的抗肿瘤剂 |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
NZ587765A (en) | 2008-03-18 | 2013-02-22 | Abbott Lab | Methods for treating psoriasis |
EP2631302A3 (en) * | 2008-03-31 | 2014-01-08 | Genentech, Inc. | Compositions and methods for treating and diagnosing asthma |
US8399630B2 (en) | 2008-08-20 | 2013-03-19 | Centocor Ortho Biotech Inc. | Engineered anti-IL-13 antibodies, compositions, methods and uses |
KR101705911B1 (ko) | 2008-09-03 | 2017-02-10 | 제넨테크, 인크. | 다중특이적 항체 |
EP2358754A1 (en) * | 2008-11-26 | 2011-08-24 | Glaxo Group Limited | Ligands that bind il-13 |
GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
ES2617777T5 (es) | 2010-04-23 | 2022-10-13 | Hoffmann La Roche | Producción de proteínas heteromultiméricas |
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
US20120237975A1 (en) | 2010-10-01 | 2012-09-20 | Jason Schrum | Engineered nucleic acids and methods of use thereof |
AU2011343570B2 (en) * | 2010-12-16 | 2016-11-03 | Genentech, Inc. | Diagnosis and treatments relating to TH2 inhibition |
WO2012097313A2 (en) | 2011-01-14 | 2012-07-19 | The Regents Of The University Of California | Therapeutic antibodies against ror-1 protein and methods for use of same |
CA2825064C (en) | 2011-02-04 | 2022-08-30 | Genentech, Inc. | Fc variants and methods for their production |
US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
EP3235508B1 (en) | 2011-03-16 | 2020-12-30 | Sanofi | Compositions comprising a dual v region antibody-like protein |
EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
CA2850624A1 (en) | 2011-10-03 | 2013-04-11 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
MX363226B (es) * | 2011-10-31 | 2019-03-15 | Genentech Inc | Formulaciones de anticuerpos. |
KR101483335B1 (ko) | 2011-11-01 | 2015-01-15 | 울산대학교 산학협력단 | 골 손실 진단 마커로서의 피브리노겐의 용도 |
KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
RU2014139546A (ru) | 2012-03-27 | 2016-05-20 | Дженентек, Инк. | Методы прогнозирования, диагностики и лечения идиопатического легочного фиброза |
CA2868398A1 (en) | 2012-04-02 | 2013-10-10 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
US9150645B2 (en) | 2012-04-20 | 2015-10-06 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
US20150140019A1 (en) * | 2012-07-13 | 2015-05-21 | The Trustees Of The University Of Pennsylvania | Compositions and Methods for Regulating CAR T Cells |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
JP6144355B2 (ja) | 2012-11-26 | 2017-06-07 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | 化学修飾mRNA |
EP2830651A4 (en) | 2013-03-12 | 2015-09-02 | Abbvie Inc | HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
WO2014165771A2 (en) * | 2013-04-05 | 2014-10-09 | Genentech, Inc. | Anti-il-4 antibodies and bispecific antibodies and uses thereof |
RU2016107435A (ru) | 2013-09-13 | 2017-10-18 | Дженентек, Инк. | Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты |
NZ756749A (en) * | 2013-09-13 | 2022-05-27 | Genentech Inc | Methods and compositions comprising purified recombinant polypeptides |
EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
BR112016018980A2 (pt) * | 2014-02-21 | 2017-10-10 | Genentech Inc | método de tratamento de um distúrbio, anticorpo multiespecífico, ácido nucleico isolado, célula hospedeira, métodos de produzir um anticorpo, de produção de uma metade de anticorpo ou de um anticorpo multiespecífico e de produção de um anticorpo multiespecífico, imunoconjugado e formulação farmacêutica |
CN106536754B (zh) * | 2014-04-11 | 2021-04-16 | 诺华股份有限公司 | 用il-13拮抗剂选择性治疗哮喘的方法 |
CN106715707A (zh) * | 2014-06-18 | 2017-05-24 | 免疫医疗公司 | 包含n‑乙酰半胱氨酸的细胞培养方法和培养基 |
RU2020141422A (ru) | 2014-11-05 | 2021-01-13 | Дженентек, Инк. | Способы получения двуцепочечных белков в бактериях |
CA2966558C (en) | 2014-11-05 | 2024-03-12 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
CR20170240A (es) | 2014-11-10 | 2018-04-03 | Genentech Inc | Anticuerpos anti-interleucina-33 y sus usos |
JP7231326B2 (ja) | 2014-11-10 | 2023-03-01 | ジェネンテック, インコーポレイテッド | Il-33媒介性障害のための治療及び診断方法 |
MX2017011486A (es) | 2015-03-16 | 2018-06-15 | Genentech Inc | Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2. |
JP7044553B2 (ja) | 2015-04-24 | 2022-03-30 | ジェネンテック, インコーポレイテッド | 結合ポリペプチドを含む細菌を特定する方法 |
CN107787332B (zh) | 2015-04-24 | 2022-09-09 | 豪夫迈·罗氏有限公司 | 多特异性抗原结合蛋白 |
KR102557643B1 (ko) | 2016-09-23 | 2023-07-20 | 제넨테크, 인크. | 아토피성 피부염을 치료하기 위한 il-13 길항제의 용도 |
US20180164221A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
AR110873A1 (es) | 2017-02-10 | 2019-05-08 | Genentech Inc | Anticuerpos contra triptasa, composiciones de estos y usos de estos |
WO2018183932A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor |
CN110770250A (zh) * | 2017-04-21 | 2020-02-07 | 金德雷德生物科学股份有限公司 | 用于兽医用途的il4/il13受体分子 |
WO2019028367A1 (en) | 2017-08-04 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES |
CN109776677B (zh) * | 2017-11-15 | 2023-11-03 | 尚华科创投资管理(江苏)有限公司 | 一种人源化抗il-13抗体及其制备方法和应用 |
CN110540590B (zh) | 2018-05-29 | 2023-08-18 | 康诺亚生物医药科技(成都)有限公司 | 一种自免疫抑制物的开发和应用 |
AU2019292580A1 (en) * | 2018-06-29 | 2021-02-04 | Krystal Biotech, Inc. | Compositions and methods for antibody delivery |
WO2020014650A1 (en) * | 2018-07-13 | 2020-01-16 | Memorial Sloan Kettering Cancer Center | Methods of using pharmacologic inhibitors of type 2 cytokine signaling to treat or prevent pancreatic cancer |
CN116726361A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
AU2020231343A1 (en) | 2019-03-06 | 2021-10-21 | Regeneron Pharmaceuticals, Inc. | IL-4/IL-13 pathway inhibitors for enhanced efficacy in treating cancer |
AU2020240132A1 (en) | 2019-03-21 | 2021-09-16 | Regeneron Pharmaceuticals, Inc. | Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy |
KR20220005568A (ko) * | 2019-05-09 | 2022-01-13 | 제넨테크, 인크. | 항체의 제조 방법 |
US20200352958A1 (en) * | 2019-05-10 | 2020-11-12 | The Trustees Of The University Of Pennsylvania | Methods And Compositions For Targeting Retinoic Acid For Solid Tumor Immunotherapy |
EP4045641A1 (en) | 2019-10-15 | 2022-08-24 | Eli Lilly and Company | Recombinantly engineered, lipase/esterase-deficient mammalian cell lines |
WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
WO2021183849A1 (en) | 2020-03-13 | 2021-09-16 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
TW202317191A (zh) | 2021-07-16 | 2023-05-01 | 美商德米拉股份有限公司 | 用於治療異位性皮炎之il-13抗體 |
TW202323291A (zh) | 2021-08-13 | 2023-06-16 | 美商德米拉股份有限公司 | 用於治療異位性皮膚炎之il-13抗體 |
WO2023044313A1 (en) | 2021-09-15 | 2023-03-23 | Dermira, Inc. | Il-13 inhibitors for the treatment of prurigo nodularis |
US20230220089A1 (en) | 2021-12-30 | 2023-07-13 | Regeneron Pharmaceuticals, Inc. | Methods for attenuating atopic march by administering an il-4/il-13 antagonist |
WO2023209568A1 (en) * | 2022-04-26 | 2023-11-02 | Novartis Ag | Multispecific antibodies targeting il-13 and il-18 |
Family Cites Families (152)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
DE3127674A1 (de) | 1981-07-14 | 1983-02-24 | Rheinmetall GmbH, 4000 Düsseldorf | Verfahren und vorrichtung zum belegen einer zielflaeche mit munition |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
WO1986005807A1 (en) | 1985-04-01 | 1986-10-09 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
WO1989004838A1 (en) | 1987-11-25 | 1989-06-01 | Immunex Corporation | Interleukin-1 receptors |
DE68921982T4 (de) | 1988-06-14 | 1996-04-25 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US5359037A (en) * | 1988-09-12 | 1994-10-25 | Yeda Research And Development Co. Ltd. | Antibodies to TNF binding protein I |
WO1990005183A1 (en) * | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
KR0184860B1 (ko) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법) |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
US5011778A (en) * | 1989-05-23 | 1991-04-30 | Otsuka Pharmaceutical Co., Ltd. | Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies |
DE69029036T2 (de) | 1989-06-29 | 1997-05-22 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
CA2071908C (en) | 1989-12-20 | 2002-04-30 | Lata Ramanathan | Antibody antagonists of human interleukin-4 |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
CA2078689C (en) | 1990-03-20 | 2003-02-11 | Sherie L. Morrison | Chimeric antibodies with receptor binding ligands in place of their constant region |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
CA2092323A1 (en) | 1990-10-01 | 1992-04-02 | George Y. Wu | Targeting viruses and cells for selective internalization by cells |
ES2129029T5 (es) | 1990-10-05 | 2005-10-16 | Celldex Therapeutics, Inc. | Inmunoestimulacion dirigida con reactivos biespecificos. |
AU8727291A (en) | 1990-10-29 | 1992-06-11 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
EP0574395B1 (en) | 1990-11-09 | 2002-06-12 | GILLIES, Stephen D. | Cytokine immunoconjugates |
DE69206301T2 (de) | 1991-03-29 | 1996-06-13 | Sanofi Sa | Protein mit der Aktivität vom Typ von Cytokin, dafür kodierende rekombinante DNS, transformierte Zellen und Mikroorganismen. |
DE69214709T2 (de) | 1991-04-26 | 1997-02-20 | Surface Active Ltd | Neue Antikörper und Verfahren zu ihrer Verwendung |
JPH06510524A (ja) | 1991-05-14 | 1994-11-24 | ユニバーシティ オブ コネチカット | 免疫原性タンパク質をコードする遺伝子の標的への配達 |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
DK0587738T3 (da) | 1991-06-05 | 2000-12-18 | Univ Connecticut | Destineret levering af gener, som koder for sekretionsproteiner |
US5994514A (en) * | 1991-08-14 | 1999-11-30 | Genentech, Inc. | Immunoglobulin variants |
US6329509B1 (en) * | 1991-08-14 | 2001-12-11 | Genentech, Inc. | Anti-IgE antibodies |
US5965709A (en) * | 1991-08-14 | 1999-10-12 | Genentech, Inc. | IgE antagonists |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
DK1024191T3 (da) | 1991-12-02 | 2008-12-08 | Medical Res Council | Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker |
AU3434393A (en) | 1992-01-17 | 1993-08-03 | Regents Of The University Of Michigan, The | Targeted virus |
WO1993015766A1 (en) | 1992-02-10 | 1993-08-19 | Seragen, Inc. | Desensitization to specific allergens |
EP0627940B1 (en) | 1992-03-05 | 2003-05-07 | Board of Regents, The University of Texas System | Use of immunoconjugates for the diagnosis and/or therapy of vascularized tumors |
WO1993020221A1 (en) | 1992-04-03 | 1993-10-14 | Young Alexander T | Gene therapy using targeted viral vectors |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
US5318564A (en) | 1992-05-01 | 1994-06-07 | Hemostatic Surgery Corporation | Bipolar surgical snare and methods of use |
DE69325777T2 (de) | 1992-06-09 | 2000-03-09 | Hoppe Ag | Riegel und türschloss |
US5397703A (en) * | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
CN1085953A (zh) * | 1992-08-21 | 1994-04-27 | 先灵公司 | 人白细胞介素13 |
US5596072A (en) * | 1992-08-21 | 1997-01-21 | Schering Corporation | Method of refolding human IL-13 |
AU5010793A (en) | 1992-08-21 | 1994-03-15 | Schering Corporation | Human interleukin-13 |
CA2141602A1 (en) | 1992-08-26 | 1994-03-03 | Philip Leder | Use of the cytokine ip-10 as an anti-tumor agent |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
DK0671923T3 (da) | 1992-10-09 | 2001-08-13 | Advanced Tissue Sciences Inc | Leverreserveceller |
AU680459B2 (en) | 1992-12-03 | 1997-07-31 | Genzyme Corporation | Gene therapy for cystic fibrosis |
US5441050A (en) | 1992-12-18 | 1995-08-15 | Neoprobe Corporation | Radiation responsive surgical instrument |
EP0604693A1 (en) | 1992-12-29 | 1994-07-06 | Schering-Plough | Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same |
AU6796094A (en) | 1993-04-29 | 1994-11-21 | Raymond Hamers | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae) |
NZ273207A (en) * | 1993-09-02 | 1997-09-22 | Dartmouth College | Igg antibodies gp39 (cd40) |
RU2162711C2 (ru) * | 1993-09-07 | 2001-02-10 | Смитклайн Бичам Корпорейшн | Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4 |
EP0659766A1 (en) | 1993-11-23 | 1995-06-28 | Schering-Plough | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
GB9415379D0 (en) * | 1994-07-29 | 1994-09-21 | Smithkline Beecham Plc | Novel compounds |
IT1270662B (it) * | 1994-10-13 | 1997-05-07 | Applied Research Systems | Antagonista della interleuchina-1 |
US5705154A (en) * | 1995-03-08 | 1998-01-06 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
US6037453A (en) * | 1995-03-15 | 2000-03-14 | Genentech, Inc. | Immunoglobulin variants |
US6518061B1 (en) * | 1995-03-15 | 2003-02-11 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
US6165463A (en) | 1997-10-16 | 2000-12-26 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
ES2304786T3 (es) | 1995-04-27 | 2008-10-16 | Amgen Fremont Inc. | Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados. |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
EP1983057A3 (en) | 1995-09-08 | 2009-01-07 | Genzyme Corporation | Improved AAV vectors for gene therapy |
EP0907730B1 (en) | 1995-10-23 | 2009-10-07 | Zenyth Operations Pty Ltd | Haemopoietin receptor and genetic sequences encoding same |
US6911530B1 (en) * | 1995-10-23 | 2005-06-28 | Amrad Operations, Pty., Ltd. | Haemopoietin receptor and genetic sequences encoding same |
FR2742156A1 (fr) | 1995-12-06 | 1997-06-13 | Sanofi Sa | Polypeptide recepteur de l'il-13 |
RU2270030C2 (ru) | 1996-02-09 | 2006-02-20 | Абботт Байотекнолоджи эЛтиди. | СПОСОБ ИНГИБИРОВАНИЯ АКТИВНОСТИ ЧЕЛОВЕЧЕСКОГО TNFα (ВАРИАНТЫ), ПРИМЕНЕНИЕ ВЫДЕЛЕННОГО АНТИТЕЛА ЧЕЛОВЕКА ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩЕГО ФРАГМЕНТА В КАЧЕСТВЕ КОМПОНЕНТА ДЛЯ ПРОИЗВОДСТВА ЛЕКАРСТВЕННОГО СРЕДСТВА (ВАРИАНТЫ) И ВЫДЕЛЕННОЕ ЧЕЛОВЕЧЕСКОЕ АНТИТЕЛО ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ |
US7078494B1 (en) * | 1996-03-01 | 2006-07-18 | Genetics Institute, Llc | Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding |
US5710023A (en) | 1996-03-01 | 1998-01-20 | Genetics Institute, Inc. | IL-13 cytokine receptor chain |
US6664227B1 (en) * | 1996-03-01 | 2003-12-16 | Genetics Institute, Llc | Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains |
WO1997033899A1 (en) | 1996-03-14 | 1997-09-18 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
CA2248868A1 (en) | 1996-03-22 | 1997-09-25 | Human Genome Sciences, Inc. | Apoptosis inducing molecule ii |
WO1997047742A1 (en) | 1996-06-12 | 1997-12-18 | Smithkline Beecham Corporation | Hr-1 receptor |
WO1998010638A1 (en) | 1996-09-10 | 1998-03-19 | Amrad Operations Pty. Ltd. | Therapeutic molecules |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
DK1500329T3 (da) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Humane antistoffer, der specifikt binder TNF-alfa |
US6743604B1 (en) * | 1996-12-13 | 2004-06-01 | Smithkline Beecham Corporation | Substances and their uses |
GB9625899D0 (en) * | 1996-12-13 | 1997-01-29 | Glaxo Group Ltd | Substances and their uses |
EA200501076A1 (ru) | 1997-01-10 | 2006-06-30 | Байоджен Айдек Ма Инк. | Лечение волчаночного нефрита с использованием анти-cd40l соединений |
CA2278106C (en) * | 1997-01-22 | 2005-04-12 | Board Of Regents, The University Of Texas System | Tissue factor methods and compositions for coagulation and tumor treatment |
WO1998046645A2 (en) | 1997-04-14 | 1998-10-22 | Micromet Gesellschaft Für Biomedizinische Forschung Mbh | Method for the production of antihuman antigen receptors and uses thereof |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US6642051B1 (en) | 1997-10-21 | 2003-11-04 | Targeted Genetics Corporation | Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors |
EP1992633A1 (en) | 1997-11-03 | 2008-11-19 | Human Genome Sciences, Inc. | VEGI, an inhibitor of angiogenesis and tumor growth |
US6576232B1 (en) * | 1998-04-03 | 2003-06-10 | The Penn State Research Foundation | IL13 mutants |
US6482403B1 (en) | 1998-05-29 | 2002-11-19 | Heska Corporation | Caniney IL-13 immunoregulatory proteins and uses thereof |
US6299875B1 (en) * | 1998-06-04 | 2001-10-09 | Panacea Pharmaceuticals, Llc | Methods to block IGE binding to cell surface receptors of mast cells |
US6222971B1 (en) | 1998-07-17 | 2001-04-24 | David Slobodin | Small inlet optical panel and a method of making a small inlet optical panel |
GB9820014D0 (en) | 1998-09-14 | 1998-11-04 | Cancer Res Campaign Tech | Receptor antagonists and uses thereof |
DE19848026A1 (de) | 1998-10-17 | 2000-04-20 | Bayer Ag | Verfahren zur Herstellung von Bis(4-hydroxyaryl)alkanen |
MXPA01006006A (es) | 1998-12-14 | 2004-08-12 | Genetics Inst | Cadena receptora de citocina. |
US7553487B2 (en) * | 1998-12-14 | 2009-06-30 | Genetics Institute, Llc | Method and compositions for treating asthma |
CA2361527C (en) | 1999-01-26 | 2004-12-14 | California Institute Of Technology | Opto-electronic oscillators having optical resonators |
AU2750800A (en) * | 1999-02-01 | 2000-08-18 | Amgen Canada Inc. | Materials and methods to inhibit hodgkin and reed sternberg cell growth |
WO2001025282A1 (en) * | 1999-10-06 | 2001-04-12 | The Penn State Research Foundation | Il13 mutants |
WO2001034645A2 (en) | 1999-11-11 | 2001-05-17 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Mutated il-13 molecules and their uses |
US7422376B2 (en) | 1999-12-07 | 2008-09-09 | Molex Incorporated | Self-contained fiber optic connector module |
CN100455599C (zh) | 2000-03-03 | 2009-01-28 | 协和发酵工业株式会社 | 基因重组抗体及其抗体片段 |
CN1323812A (zh) | 2000-05-16 | 2001-11-28 | 上海博德基因开发有限公司 | 一种新的多肽——人白细胞介素-13(il-13)受体11和编码这种多肽的多核苷酸 |
AU1091802A (en) | 2000-10-20 | 2002-04-29 | Chugai Pharmaceutical Co Ltd | Degraded agonist antibody |
DE60135481D1 (de) | 2000-10-20 | 2008-10-02 | Genetics Inst | Verwendung von il-13 inhibitoren zur behandlung von tumoren |
JP4052515B2 (ja) | 2001-08-31 | 2008-02-27 | 協和醗酵工業株式会社 | ヒト型cdr移植抗体およびその抗体断片 |
US6908963B2 (en) * | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
US20040023337A1 (en) | 2001-10-26 | 2004-02-05 | Heavner George A. | IL-13 mutein proteins, antibodies, compositions, methods and uses |
CN1321695C (zh) | 2001-11-07 | 2007-06-20 | 赛托斯生物技术公司 | 用于治疗变应性嗜酸细胞性疾病的展示il-5、il-3或嗜酸细胞活化趋化因子的抗原阵列 |
AU2002258011B2 (en) * | 2001-12-04 | 2009-01-08 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health | Chimeric molecule for the treatment of TH2-like cytokine mediated disorders |
AU2003225727A1 (en) * | 2002-03-08 | 2003-09-22 | Rigel Pharmaceuticals, Inc. | COMPOUNDS THAT MODULATE PROCESSES ASSOCIATED WITH IgE PRODUCTION AND METHODS AND KITS FOR IDENTIFYING AND USING THE SAME |
US20030170724A1 (en) * | 2002-03-08 | 2003-09-11 | Anderson David C. | Methods of identifying target polypeptides |
WO2003086451A1 (en) * | 2002-04-05 | 2003-10-23 | Centocor, Inc. | Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses |
JP4689268B2 (ja) | 2002-06-14 | 2011-05-25 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Il−13およびnk−t細胞に関する、結腸炎を処置および予防する方法 |
US7374894B2 (en) * | 2002-07-16 | 2008-05-20 | Rigel Pharmaceuticals, Inc. | Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a chloride intracellular channel 1 protein |
JP2006501249A (ja) | 2002-08-30 | 2006-01-12 | グラクソ グループ リミテッド | ワクチン |
AR041086A1 (es) | 2002-08-30 | 2005-04-27 | Glaxo Group Ltd | Vacuna |
NZ593428A (en) * | 2002-09-06 | 2013-01-25 | Amgen Inc | Therapeutic human anti-il-1r1 monoclonal antibody |
ES2566778T3 (es) | 2003-02-01 | 2016-04-15 | Tanox, Inc. | Anticuerpos anti-IgE de humano de alta afinidad |
DK1471057T3 (da) * | 2003-04-25 | 2006-05-15 | Actimis Pharmaceuticals Inc | Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2 |
GB0407315D0 (en) | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
JP4943161B2 (ja) * | 2003-12-23 | 2012-05-30 | ジェネンテック, インコーポレイテッド | 新規抗il13モノクローナル抗体での癌の処置 |
AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
KR101363777B1 (ko) | 2005-09-30 | 2014-02-14 | 메디뮨 리미티드 | 인터루킨―13 항체 조성물 |
EP2532679B1 (en) | 2005-10-21 | 2017-04-12 | Novartis AG | Human antibodies against il13 and therapeutic uses |
WO2008140455A1 (en) | 2007-05-15 | 2008-11-20 | Tanox, Inc. | Treatment of radiation and chemo-therapy induced fibrosis using novel anti-il 13 monoclonal antibodies |
EP2631302A3 (en) | 2008-03-31 | 2014-01-08 | Genentech, Inc. | Compositions and methods for treating and diagnosing asthma |
AU2011343570B2 (en) | 2010-12-16 | 2016-11-03 | Genentech, Inc. | Diagnosis and treatments relating to TH2 inhibition |
-
2004
- 2004-12-23 JP JP2006547441A patent/JP4943161B2/ja active Active
- 2004-12-23 AT AT04815562T patent/ATE552850T1/de active
- 2004-12-23 US US10/583,927 patent/US8067199B2/en active Active
- 2004-12-23 SG SG200901976-1A patent/SG151296A1/en unknown
- 2004-12-23 SG SG10201900535UA patent/SG10201900535UA/en unknown
- 2004-12-23 EP EP10178487A patent/EP2351584A1/en not_active Withdrawn
- 2004-12-23 AU AU2004308494A patent/AU2004308494B2/en active Active
- 2004-12-23 JP JP2006547431A patent/JP4851944B2/ja active Active
- 2004-12-23 PL PL14164624T patent/PL2805728T3/pl unknown
- 2004-12-23 KR KR1020127001379A patent/KR20120020203A/ko active Application Filing
- 2004-12-23 WO PCT/US2004/043541 patent/WO2005062972A2/en active Application Filing
- 2004-12-23 CN CN201210299210.6A patent/CN102993302B/zh active Active
- 2004-12-23 FI FIEP20155148.8T patent/FI3718564T3/fi active
- 2004-12-23 KR KR1020137007978A patent/KR20130041373A/ko active Application Filing
- 2004-12-23 ES ES10179775.1T patent/ES2533084T3/es active Active
- 2004-12-23 MX MX2015002420A patent/MX361174B/es unknown
- 2004-12-23 LT LTEP14164624.0T patent/LT2805728T/lt unknown
- 2004-12-23 US US10/583,926 patent/US7674459B2/en active Active
- 2004-12-23 SI SI200431935T patent/SI1711528T1/sl unknown
- 2004-12-23 SI SI200431888T patent/SI1703893T1/sl unknown
- 2004-12-23 SI SI200432492T patent/SI2805728T1/sl unknown
- 2004-12-23 DK DK20155148.8T patent/DK3718564T3/da active
- 2004-12-23 CN CN201410077001.6A patent/CN104013957B/zh active Active
- 2004-12-23 ES ES04815598T patent/ES2390344T3/es active Active
- 2004-12-23 DK DK04815562.6T patent/DK1703893T3/da active
- 2004-12-23 SG SG2012070413A patent/SG184774A1/en unknown
- 2004-12-23 RU RU2006122037/10A patent/RU2487887C2/ru active
- 2004-12-23 HR HRP20231569TT patent/HRP20231569T1/hr unknown
- 2004-12-23 PL PL04815598T patent/PL1711528T3/pl unknown
- 2004-12-23 EP EP10179775.1A patent/EP2332575B1/en active Active
- 2004-12-23 CN CNA2004800388204A patent/CN1898264A/zh active Pending
- 2004-12-23 EP EP04815598A patent/EP1711528B1/en active Active
- 2004-12-23 WO PCT/US2004/043501 patent/WO2005062967A2/en active Application Filing
- 2004-12-23 HU HUE14164624A patent/HUE049161T2/hu unknown
- 2004-12-23 CA CA2551110A patent/CA2551110C/en active Active
- 2004-12-23 PL PL20155148.8T patent/PL3718564T3/pl unknown
- 2004-12-23 DK DK04815598.0T patent/DK1711528T3/da active
- 2004-12-23 PT PT201551488T patent/PT3718564T/pt unknown
- 2004-12-23 PT PT04815562T patent/PT1703893E/pt unknown
- 2004-12-23 PT PT141646240T patent/PT2805728T/pt unknown
- 2004-12-23 KR KR1020067014859A patent/KR101280338B1/ko active IP Right Grant
- 2004-12-23 EP EP20155148.8A patent/EP3718564B1/en active Active
- 2004-12-23 CA CA2550651A patent/CA2550651C/en active Active
- 2004-12-23 EP EP04815562A patent/EP1703893B1/en active Active
- 2004-12-23 ES ES04815562T patent/ES2385038T3/es active Active
- 2004-12-23 PL PL04815562T patent/PL1703893T3/pl unknown
- 2004-12-23 KR KR1020147003706A patent/KR101627588B1/ko active IP Right Grant
- 2004-12-23 ES ES14164624T patent/ES2775204T3/es active Active
- 2004-12-23 SI SI200432525T patent/SI3718564T1/sl unknown
- 2004-12-23 LT LTEP20155148.8T patent/LT3718564T/lt unknown
- 2004-12-23 KR KR1020157014126A patent/KR20150064250A/ko not_active Application Discontinuation
- 2004-12-23 CN CN2004800386571A patent/CN1973053B/zh active Active
- 2004-12-23 DK DK14164624.0T patent/DK2805728T3/da active
- 2004-12-23 SG SG10201404273QA patent/SG10201404273QA/en unknown
- 2004-12-23 EP EP14164624.0A patent/EP2805728B1/en active Active
-
2006
- 2006-05-31 IL IL176042A patent/IL176042A/en active IP Right Grant
-
2007
- 2007-01-25 JP JP2007015642A patent/JP2007161724A/ja active Pending
- 2007-11-30 HK HK07113106.7A patent/HK1108007A1/xx unknown
-
2008
- 2008-09-29 US US12/240,604 patent/US8088618B2/en active Active
-
2010
- 2010-01-14 US US12/687,637 patent/US8318160B2/en active Active
- 2010-10-15 JP JP2010233095A patent/JP2011042669A/ja active Pending
-
2011
- 2011-05-18 JP JP2011111913A patent/JP2011200242A/ja not_active Withdrawn
- 2011-10-18 US US13/275,684 patent/US8734801B2/en active Active
- 2011-10-18 US US13/275,658 patent/US8734797B2/en active Active
- 2011-11-30 US US13/308,186 patent/US9067994B2/en active Active
-
2012
- 2012-05-03 HR HRP20120376TT patent/HRP20120376T1/hr unknown
- 2012-05-31 CY CY20121100496T patent/CY1113009T1/el unknown
- 2012-06-05 RU RU2012123148/10A patent/RU2012123148A/ru unknown
-
2013
- 2013-08-20 US US13/971,394 patent/US9605065B2/en active Active
-
2014
- 2014-04-23 IL IL232210A patent/IL232210A0/en unknown
-
2015
- 2015-02-27 HK HK15102008.9A patent/HK1201457A1/xx unknown
- 2015-05-23 HK HK15104923.7A patent/HK1204288A1/xx unknown
-
2017
- 2017-09-29 US US15/721,570 patent/US20180251538A1/en not_active Abandoned
-
2019
- 2019-11-13 US US16/682,773 patent/US11434287B2/en active Active
-
2020
- 2020-02-13 RU RU2020106818A patent/RU2752833C1/ru active
- 2020-04-14 HR HRP20200592TT patent/HRP20200592T1/hr unknown
- 2020-04-28 CY CY20201100385T patent/CY1122817T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20200592T1 (hr) | Nova anti-il 13 antitijela i njihove uporabe | |
JP2006516409A5 (hr) | ||
JP2019122405A5 (hr) | ||
US11919950B2 (en) | Expression vector encoding antibody molecule which binds IL-17A and IL-17F | |
JP2022075818A5 (hr) | ||
HRP20170407T1 (hr) | Anti-epha2 anitijelo | |
ES2635594T3 (es) | Proteínas de unión a IL-1 | |
RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
RU2588467C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
JP2020517249A5 (hr) | ||
US20160039929A1 (en) | Antibody molecules having specificity for human il-6 | |
RU2007103826A (ru) | Иммуноглобулины | |
RU2012112829A (ru) | Анти-gitr-антитела | |
JP2017534577A5 (hr) | ||
JP2023134618A5 (hr) | ||
JP2012511329A5 (hr) | ||
HRP20160494T1 (hr) | Antigen-vezujući proteini za proproteinsku konvertazu subtilizin keksin tipa 9 (pcsk9) | |
HRP20120606T4 (hr) | Protutijela protiv il-17 | |
RU2012142311A (ru) | Интерлейкин-13-связывающие белки | |
PE20081185A1 (es) | Anticuerpos que se unen a interleucina 13 (il-13) humana y composiciones farmaceuticas que lo comprenden | |
JP2007527406A5 (hr) | ||
JP2012532851A5 (hr) | ||
RU2009111884A (ru) | Последовательности вариабельных областей моноклональных антител против il-31 и способы использования | |
JP2009523154A5 (hr) | ||
HRP20110758T1 (hr) | Antagonistička protutijela na il-17 |